Skip to main content

Table 3 Relative risk of poor clinical response

From: Effect of prior antibiotic or chemotherapy treatment on immunotherapy response in non-small cell lung cancer

  Best Response in 6 months      
  CR/PR (n = 71) SD/PD (n = 185) Univariate Multivariate1 Multivariate2
  N (%) N (%) Relative Risk (95% CI) Relative Risk (95% CI) P-value Relative Risk (95% CI) P-value
Antibiotic Use
 ATB- 59 (28.1) 151 (71.9) 1.00 1.00   1.00  
 ATB +  12 (26.1) 34 (73.9) 1.03 (0.85–1.24) 1.04 (0.88–1.24) 0.633 1.08 (0.93–1.26) 0.321
PPI Use
 No 50 (25.6) 145 (74.4) 1.00 1.00   1.00  
 Yes 21 (34.4) 40 (65.6) 1.00 (0.82–1.22) 1.00 (0.83–1.21) 1.000 1.00 (0.82–1.21) 1.000
Prior Chemotherapy
 No 41 (37.3) 69 (62.7) 1.00 1.00   1.00  
 Yes 30 (20.5) 116 (79.5) 1.27 (1.07–1.50) 1.26 (1.07–1.48) 0.007* 1.24 (1.05–1.47) 0.013*
Age (binary)
  <  = 67 39 (27.5) 103 (72.5) 1.00 NA NA 1.00  
  > 67 32 (28.1) 82 (71.9) 1.00 (0.86, 1.17) NA NA 1.00 (0.87–1.15) 1.000
ECOG Performance Status
 0 18 (31.6) 39 (68.4) 1.00 NA NA 1.00  
 1/2 53 (26.8) 145 (73.2) 1.07 (0.88–1.30) NA NA 1.06 (0.89–1.26) 0.530
Targeted Therapy
 No 64 (29.8) 151 (70.2) 1.00 NA NA 1.00  
 Yes 7 (17.1) 34 (82.9) 1.18 (1.00–1.39) NA NA 1.11 (0.95–1.29) 0.188
  1. *Statistically Significant, when p < 0.05; 1: Adjusted for significant risk factors in Table 1/adjusted for PPI and Chemotherapy; 2: Adjusted for PPI, Chemotherapy, Age (cut at the median age of 67), ECOG (0 vs. combined 1/2), and Targeted Therapy; *Negative response ( SD&PD) is considered as event/1. Positive response (CR&PR) is considered as reference/0. CR complete response, PP Proton pump inhibitor, PR partial response, PD progressive disease, SD Stable disease